Clinical Trial Update: Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy [Phase 2]

View source ↗

Summary

This entry reports a Phase 2 clinical trial evaluating ranibizumab for residual diabetic macular edema after prior anti-VEGF therapy; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Vitreo-Retinal Associates, PC | Conditions: Diabetic Macular Edema | Phase 2 | Status: COMPLETED